Coherus Oncology, Inc. (NASDAQ:CHRS – Get Free Report) saw a large decrease in short interest during the month of October. As of October 15th, there was short interest totaling 12,452,177 shares, a decrease of 46.6% from the September 30th total of 23,337,539 shares. Approximately 8.7% of the company’s stock are sold short. Based on an average daily trading volume, of 1,579,236 shares, the days-to-cover ratio is presently 7.9 days.
Institutional Trading of Coherus Oncology
Several hedge funds have recently modified their holdings of CHRS. Spark Investment Management LLC bought a new stake in Coherus Oncology in the 2nd quarter valued at about $25,000. Cetera Investment Advisers bought a new stake in Coherus Oncology in the first quarter worth about $54,000. The Manufacturers Life Insurance Company purchased a new position in shares of Coherus Oncology during the 2nd quarter valued at $54,000. Dimensional Fund Advisors LP bought a new position in Coherus Oncology in the 1st quarter worth approximately $60,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Coherus Oncology during the second quarter valued at about $131,000. Institutional investors own 72.82% of the company’s stock.
Wall Street Analyst Weigh In
CHRS has been the topic of a number of recent analyst reports. Weiss Ratings raised Coherus Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 26th. HC Wainwright assumed coverage on shares of Coherus Oncology in a research report on Thursday. They set a “buy” rating on the stock. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.
Get Our Latest Analysis on CHRS
Trending Headlines about Coherus Oncology
Here are the key news stories impacting Coherus Oncology this week:
- Positive Sentiment: Early data for tagmokitug reportedly support advancing the program into a broader study, providing a potential catalyst for Coherus’s pipeline and future value. However, additional study and regulatory risks remain. Coherus Oncology stock: Tagmokitug data support broader study
- Positive Sentiment: HC Wainwright initiated coverage with a Buy rating, signaling a favorable view of Coherus’s longer-term prospects. The firm projects earnings to turn positive in fiscal 2030, at approximately $0.19 per share. HC Wainwright Initiates Coverage on Coherus Oncology
- Neutral Sentiment: HC Wainwright estimates losses of $0.91 per share for fiscal 2026 and $0.63 per share for fiscal 2027, improving to $0.48 in 2028 and $0.19 in 2029. The forecasts suggest gradual improvement but no near-term profitability.
- Negative Sentiment: The company is expected to remain loss-making across the near-term quarterly forecasts, including projected losses of $0.22 per share in Q3 2026, $0.21 in Q4 2026, and roughly $0.17 per share in the first half of 2027. Persistent cash needs and development costs may continue to weigh on the stock.
Coherus Oncology Price Performance
Shares of CHRS traded down $0.07 during trading hours on Friday, reaching $0.83. The stock had a trading volume of 2,185,506 shares, compared to its average volume of 1,595,360. The company’s 50-day moving average is $1.20 and its two-hundred day moving average is $1.53. Coherus Oncology has a 12 month low of $0.81 and a 12 month high of $2.62. The stock has a market capitalization of $128.25 million, a PE ratio of -0.81 and a beta of 0.98. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.70 and a current ratio of 1.77.
Coherus Oncology (NASDAQ:CHRS – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.06. The company had revenue of $14.31 million during the quarter, compared to the consensus estimate of $14.41 million. Coherus Oncology had a negative return on equity of 222.75% and a negative net margin of 259.41%. Research analysts expect that Coherus Oncology will post -0.88 EPS for the current year.
Coherus Oncology Company Profile
Coherus Oncology, formerly known as Coherus BioSciences, is a commercial-stage biopharmaceutical company focused primarily on developing and commercializing medicines for cancer and other serious diseases. The company has built its business around biologic therapies, including biosimilars and innovative treatments intended to improve access to important medicines.
Its portfolio includes UDENYCA (pegfilgrastim-cbq), a long-acting treatment used to reduce the risk of infection associated with chemotherapy, and LOQTORZI (toripalimab-tpzi), an immuno-oncology therapy approved in the United States for certain patients with nasopharyngeal carcinoma.
Featured Articles
- Five stocks we like better than Coherus Oncology
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Coherus Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
